Regulatory S16 Ep40: FDA Approval Insights: Zongertinib for HER2 TKD-Mutated NSCLC: With Julia Rotow, MD; and Martin Dietrich, MD, PhD OncLive PodcastIn today's episode, we spoke with Julia Rotow, MD, and Martin Dietrich, MD, PhD.RegulatoryOncologyRead full story pharminent March 30, 2026 (Last updated: March 31, 2026) OncLive Podcast In today’s episode, we spoke with Julia Rotow, MD, and Martin Dietrich, MD, PhD. RegulatoryOncologyRead full story Post navigation Previous: Blackstone closes $6.3B fund for life sciences investingNext: AZ considers filings for long-acting Strensiq follow-up Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
